Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea
© 2024 The Korean Academy of Medical Sciences..
BACKGROUND: Bivalent booster mRNA vaccines containing the omicron-variant strains have been introduced worldwide in the autumn of 2022. Nevertheless, the omicron subvariants evoked another large coronavirus disease 2019 (COVID-19) pandemic wave in late 2022 and early 2023.
METHODS: A retrospective, test-negative, case-control study was conducted to estimate the vaccine effectiveness (VE) of bivalent COVID-19 vaccines in 8 university hospitals between January and February 2023. The case and control groups were divided based on nasopharyngeal COVID-19 real-time polymerase chain reaction results and matched based on age, sex, hospital, and date (week) of the test performed. The VE of the BA.1- or BA.4/BA.5-based mRNA vaccines were estimated. VE was calculated using the 1-adjusted odds ratio from multivariable logistic regression.
RESULTS: In total, 949 patients and 947 controls were enrolled in this study. VE for the BA.4/BA.5-based bivalent mRNA vaccine was 43% (95% confidence interval [CI], 17, 61%). In subgroup analysis based on age and underlying medical conditions, BA.4/BA.5-based bivalent mRNA vaccine was effective against old adults aged ≥ 65-years (VE, 55%; 95% CI, 23, 73%) and individuals with comorbidities (VE, 54%; 95% CI, 23, 73%). In comparison, the BA.1-based bivalent mRNA vaccine did not demonstrate statistically significant effectiveness (VE, 25%; 95% CI, -8, 49%).
CONCLUSION: The BA.4/BA.5-based bivalent mRNA booster vaccine provided significant protection against COVID-19 in the Korean adults, especially in the older adults aged ≥ 65 years and in individuals with underlying medical conditions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Journal of Korean medical science - 39(2024), 3 vom: 22. Jan., Seite e15 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoon, Jin Gu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 24.01.2024 Date Revised 27.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3346/jkms.2024.39.e15 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367488442 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367488442 | ||
| 003 | DE-627 | ||
| 005 | 20240127231924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240123s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3346/jkms.2024.39.e15 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1272.xml |
| 035 | |a (DE-627)NLM367488442 | ||
| 035 | |a (NLM)38258360 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoon, Jin Gu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2024 | ||
| 500 | |a Date Revised 27.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Korean Academy of Medical Sciences. | ||
| 520 | |a BACKGROUND: Bivalent booster mRNA vaccines containing the omicron-variant strains have been introduced worldwide in the autumn of 2022. Nevertheless, the omicron subvariants evoked another large coronavirus disease 2019 (COVID-19) pandemic wave in late 2022 and early 2023 | ||
| 520 | |a METHODS: A retrospective, test-negative, case-control study was conducted to estimate the vaccine effectiveness (VE) of bivalent COVID-19 vaccines in 8 university hospitals between January and February 2023. The case and control groups were divided based on nasopharyngeal COVID-19 real-time polymerase chain reaction results and matched based on age, sex, hospital, and date (week) of the test performed. The VE of the BA.1- or BA.4/BA.5-based mRNA vaccines were estimated. VE was calculated using the 1-adjusted odds ratio from multivariable logistic regression | ||
| 520 | |a RESULTS: In total, 949 patients and 947 controls were enrolled in this study. VE for the BA.4/BA.5-based bivalent mRNA vaccine was 43% (95% confidence interval [CI], 17, 61%). In subgroup analysis based on age and underlying medical conditions, BA.4/BA.5-based bivalent mRNA vaccine was effective against old adults aged ≥ 65-years (VE, 55%; 95% CI, 23, 73%) and individuals with comorbidities (VE, 54%; 95% CI, 23, 73%). In comparison, the BA.1-based bivalent mRNA vaccine did not demonstrate statistically significant effectiveness (VE, 25%; 95% CI, -8, 49%) | ||
| 520 | |a CONCLUSION: The BA.4/BA.5-based bivalent mRNA booster vaccine provided significant protection against COVID-19 in the Korean adults, especially in the older adults aged ≥ 65 years and in individuals with underlying medical conditions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 Omicron Variant | |
| 650 | 4 | |a Vaccine Efficacy | |
| 650 | 4 | |a mRNA Vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Sohn, Jang Wook |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Won Suk |e verfasserin |4 aut | |
| 700 | 1 | |a Wie, Seong-Heon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jin-Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Hye Won |e verfasserin |4 aut | |
| 700 | 1 | |a Eom, Joong Sik |e verfasserin |4 aut | |
| 700 | 1 | |a Seong, Hye |e verfasserin |4 aut | |
| 700 | 1 | |a Nham, Eliel |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Yu Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Noh, Ji Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Joon Young |e verfasserin |4 aut | |
| 700 | 1 | |a Cheong, Hee Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Woo Joo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Korean medical science |d 1995 |g 39(2024), 3 vom: 22. Jan., Seite e15 |w (DE-627)NLM012649317 |x 1598-6357 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2024 |g number:3 |g day:22 |g month:01 |g pages:e15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3346/jkms.2024.39.e15 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2024 |e 3 |b 22 |c 01 |h e15 | ||